bezuclastinib
bezuclastinib: sourced relationships with 1 company · 4 clinical trials tracked.
bezuclastinib evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
How could bezuclastinib → COGT affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| Cogent Biosciences, Inc. (COGT) Advanced Systemic Mastocytosis (AdvSM); SSM; Systemic Mastoc… | Phase 3 |
| Cogent Biosciences, Inc. (COGT) Advanced Systemic Mastocytosis (AdvSM); SSM; Systemic Mastoc… | Phase 2 |
Clinical Trial Registry Records (4)
Intermediate-Size Patient Population Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors
A Multi-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of The Safety and Efficacy of CGT9486 in Subjects With Nonadvanced Systemic Mastocytosis
Primary endpoint: Part 1: Determine recommended dose of bezuclastinib (CGT9486) in subjects with NonAdvSM
A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis
Primary endpoint: Part I: Identify clinically active and tolerable exposures of bezuclastinib in patients with AdvSM
Frequently asked questions
Which companies have sourced relationships with bezuclastinib?
bezuclastinib has dated SEC/FDA relationship records for Cogent Biosciences, Inc..
How many clinical trials involve bezuclastinib?
BioSniper tracks 4 clinical trials involving bezuclastinib.